# Silence Therapeutics (SLN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SLN
## Company Profile
- Ticker: SLN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
- Tags: Nucleic Acid Drugs, Hematology
## Stock Data
- Close: 9.52 USD
- Market cap: 300884484.81 USD
- Last updated: 2026-10-08
## Business Overview
Silence Therapeutics is an RNA interference company focused on targeted gene silencing. Its story is built around translating RNAi into precision medicines for cardiovascular and hematologic disease.
## Why The Stock Is Moving

As of Oct 8, 2026, SLN closed down 3.05% at $9.52. No new same-company headline was identified in the current news window.

## Geographic Base

Silence Therapeutics is headquartered in the United Kingdom and listed on NASDAQ. It sits in RNA therapeutics and platform biotechnology.

## Business Model

The company depends on translational validation, clinical progress, and the ability to turn RNAi science into durable therapeutic value. Investors watch data, partnerships, and pipeline execution.

## Landscape Position

Silence occupies a premium RNAi niche within biotech. The stock is sensitive to whether the platform can keep validating beyond the first wave of programs.

## Future Catalysts

- Silence Therapeutics’ catalysts are RNAi-platform programs and any clinical update that shows the delivery / target-silencing story still has real momentum. The company remains very platform-dependent.

## Recent News
- 2022-01-05 12:00 EST — [Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference](https://biopharmsignal.com/news/SLN/silence-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnec-e6e15404) — Source: Silence Therapeutics
- 2021-12-12 14:01 EST — [New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases](https://biopharmsignal.com/news/SLN/new-data-from-sln124-healthy-volunteer-study-reinforce-broad-therapeutic-potenti-acc14ba1) — Source: Silence Therapeutics
- 2021-12-01 12:00 EST — [Silence Therapeutics Welcomes Deep Track Capital as New Shareholder](https://biopharmsignal.com/news/SLN/silence-therapeutics-welcomes-deep-track-capital-as-new-shareholder-cf59d84c) — Source: Silence Therapeutics
- 2021-11-30 12:00 EST — [Silence Therapeutics Begins Exclusive Nasdaq Trading](https://biopharmsignal.com/news/SLN/silence-therapeutics-begins-exclusive-nasdaq-trading-bb877fe3) — Source: Silence Therapeutics
- 2021-11-11 12:00 EST — [Silence Therapeutics to Present at Jefferies London Healthcare Conference](https://biopharmsignal.com/news/SLN/silence-therapeutics-to-present-at-jefferies-london-healthcare-conference-cb7ad5ab) — Source: Silence Therapeutics